Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.03, FiscalAI reports. Maravai LifeSciences had a negative return on equity of 15.70% and a negative net margin of 37.07%. The business had revenue of $45.85 million during the quarter, compared to analysts’ expectations of $43.56 million.
Here are the key takeaways from Maravai LifeSciences’ conference call:
- Q3 revenue rose 10% to $45.9 million, led by mRNA growth of 28% (GMP consumables +30%, discovery mRNA +27%). Cygnus grew 8%, marking its sixth consecutive quarter of year-over-year growth.
- Adjusted EBITDA improved by $16.6 million year over year to $5.8 million, and Maravai raised its 2026 revenue outlook to $212–$216 million and adjusted EBITDA outlook to $40–$42 million.
- Management cited a healthy mRNA pipeline and growing customer adoption: 10 discovery customers transitioned to clinical-stage GMP year to date, surpassing the company’s target of nine, and more than 180 customers are using ModTail.
- Management cautioned that GMP and CDMO orders are program-driven and can vary significantly by quarter; it expects GMP activity to skew toward the second half of 2027 and does not anticipate substantial 2027 GMP revenue from ModTail. Specialty chemistry revenue also declined 4% as large prior-year orders did not repeat.
Maravai LifeSciences Price Performance
Shares of NASDAQ:MRVI traded up $0.27 during midday trading on Wednesday, reaching $7.71. The company had a trading volume of 3,624,037 shares, compared to its average volume of 2,400,230. The company has a current ratio of 4.05, a quick ratio of 2.98 and a debt-to-equity ratio of 0.49. Maravai LifeSciences has a 1-year low of $2.55 and a 1-year high of $9.42. The company has a fifty day simple moving average of $7.45 and a two-hundred day simple moving average of $5.27.
Wall Street Analyst Weigh In
Several equities research analysts have commented on MRVI shares. Wall Street Zen cut shares of Maravai LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 29th. TD Cowen started coverage on shares of Maravai LifeSciences in a report on Monday, October 5th. They issued a “buy” rating and a $9.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Wednesday, August 26th. UBS Group raised their target price on shares of Maravai LifeSciences from $2.50 to $8.00 and gave the stock a “neutral” rating in a report on Wednesday, September 9th. Finally, Wells Fargo & Company lifted their price target on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.38.
View Our Latest Stock Analysis on MRVI
Maravai LifeSciences Company Profile
Maravai LifeSciences Holdings, Inc is a life sciences company that provides products and services used in the development, manufacture and quality testing of biopharmaceuticals, vaccines and diagnostic products. The company serves pharmaceutical, biotechnology, academic and other research organizations involved in nucleic acid and biologics development.
Through its TriLink BioTechnologies business, Maravai supplies specialized nucleic acid products and services, including modified nucleotides, messenger RNA-related materials, enzymes and other components used in research and biomanufacturing.
Further Reading
- Five stocks we like better than Maravai LifeSciences
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
